Evidence map›Paper›PMID 33332560›Full record

ArticleNucleic acids research2021

The mTOR regulated RNA-binding protein LARP1 requires PABPC1 for guided mRNA interaction.

Ewan M Smith, Nour El Houda Benbahouche, Katherine Morris, Ania Wilczynska, Sarah Gillen, Tobias Schmidt, Hedda A Meijer, Rebekah Jukes-Jones, Kelvin Cain, Carolyn Jones and 7 more

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Ribosome biogenesis in disease: new players and therapeutic targets.Signal transduction and targeted therapy · 2023
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Conserved Functions of LARP1 Proteins in Eukaryotes.Wiley interdisciplinary reviews. RNA
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Ewan M SmithCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Nour El Houda BenbahoucheCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Katherine MorrisMRC Toxicology Unit, University of Cambridge, Leicester LE1 9HN, UK.
Ania WilczynskaCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Sarah GillenCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Tobias SchmidtCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Hedda A MeijerDivision of Cell and Developmental Biology, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK.
Rebekah Jukes-JonesMRC Toxicology Unit, University of Cambridge, Leicester LE1 9HN, UK.
Kelvin CainMRC Toxicology Unit, University of Cambridge, Leicester LE1 9HN, UK.
Carolyn JonesMRC Toxicology Unit, University of Cambridge, Leicester LE1 9HN, UK.
Mark StoneleyMRC Toxicology Unit, University of Cambridge, Leicester LE1 9HN, UK.
Joseph A WaldronCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Cameron BellCancer Research UK Therapeutic Discovery Laboratories, London Bioscience Innovation Centre, 2 Royal College Street, London NW1 0NH, UK.
Bruno D FonsecaPrimerGen Ltd, Viseu, Portugal.
Sarah BlagdenDepartment of Oncology, University of Oxford, Oxford, OX3 7LE, UK.
Anne E WillisMRC Toxicology Unit, University of Cambridge, Leicester LE1 9HN, UK.
Martin BushellCancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, UK.
Cancer Research UK · GBUniversity of Cambridge · GBUniversity of Dundee · GBUniversity of Oxford · GB

Funding

Cancer Research UK 22598Cancer Research UK 24388Cancer Research UK 29252Cancer Research UK 30062Medical Research Council 1243972Medical Research Council MC_EX_G0902052Medical Research Council MC_UP_A600_1023Medical Research Council MC UP A600 1024Medical Research Council MC_UP_A600_1024Medical Research Council MC_UU_00025/6Medical Research Council MC_UU_00025/7
6 · The paper itself

Abstract

The mammalian target of rapamycin (mTOR) is a critical regulator of cell growth, integrating multiple signalling cues and pathways. Key among the downstream activities of mTOR is the control of the protein synthesis machinery. This is achieved, in part, via the co-ordinated regulation of mRNAs that contain a terminal oligopyrimidine tract (TOP) at their 5'ends, although the mechanisms by which this occurs downstream of mTOR signalling are still unclear. We used RNA-binding protein (RBP) capture to identify changes in the protein-RNA interaction landscape following mTOR inhibition. Upon mTOR inhibition, the binding of LARP1 to a number of mRNAs, including TOP-containing mRNAs, increased. Importantly, non-TOP-containing mRNAs bound by LARP1 are in a translationally-repressed state, even under control conditions. The mRNA interactome of the LARP1-associated protein PABPC1 was found to have a high degree of overlap with that of LARP1 and our data show that PABPC1 is required for the association of LARP1 with its specific mRNA targets. Finally, we demonstrate that mRNAs, including those encoding proteins critical for cell growth and survival, are translationally repressed when bound by both LARP1 and PABPC1.

Indexed as

5' Untranslated RegionsAutoantigensGene Expression RegulationGenes, ReporterHeLa CellsHumansMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Mutagenesis, Site-DirectedMutation, MissenseNaphthyridinesPoint MutationPoly(A)-Binding Protein IPolyribosomesProtein BiosynthesisRecombinant Fusion Proteins1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one5' Untranslated RegionsAutoantigensMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2MTOR protein, humanNaphthyridinesPoly(A)-Binding Protein IRecombinant Fusion ProteinsRibonucleoproteinsRNA-Binding ProteinsRNA, MessengerSS-B AntigenTOR Serine-Threonine Kinases

Identifiers

PMID33332560
PMCPMC7797073
OpenAlexW3114983004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.